These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21499112)

  • 21. Antiretroviral treatment initiation among HIV-infected pregnant women with low CD4(+) cell counts in Gaborone, Botswana.
    Chen JY; Ogwu AC; Svab P; Lockman S; Moffat HJ; Gaolathe T; Moilwa S; Størdal K; Dryden-Peterson S; Moffat C; Makhema J; Essex M; Shapiro RL
    J Acquir Immune Defic Syndr; 2010 May; 54(1):102-6. PubMed ID: 19864957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiretroviral therapy in antenatal care to increase treatment initiation in HIV-infected pregnant women: a stepped-wedge evaluation.
    Killam WP; Tambatamba BC; Chintu N; Rouse D; Stringer E; Bweupe M; Yu Y; Stringer JS
    AIDS; 2010 Jan; 24(1):85-91. PubMed ID: 19809271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pregnancy Profile and Infant Outcomes Among HIV Infected Women Who Delivered in Cipto Mangunkusumo Hospital.
    Indarti J; Yunihastuti E; Kurniati N; Aprilia B; Pamungkas DT; Chiprion AT; Ginting MA; Rizal S; Dewi C; Handayani L
    Acta Med Indones; 2020 Jan; 52(1):55-62. PubMed ID: 32291372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pregnancy and HIV Disease Progression in an Early Infection Cohort from Five African Countries.
    Wall KM; Rida W; Haddad LB; Kamali A; Karita E; Lakhi S; Kilembe W; Allen S; Inambao M; Yang AH; Latka MH; Anzala O; Sanders EJ; Bekker LG; Edward VA; Price MA
    Epidemiology; 2017 Mar; 28(2):224-232. PubMed ID: 27893488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential impact of new WHO criteria for antiretroviral treatment for prevention of mother-to- child HIV transmission.
    Kuhn L; Aldrovandi GM; Sinkala M; Kankasa C; Mwiya M; Thea DM
    AIDS; 2010 Jun; 24(9):1374-7. PubMed ID: 20568677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Point-of-care CD4 testing to inform selection of antiretroviral medications in south african antenatal clinics: a cost-effectiveness analysis.
    Ciaranello AL; Myer L; Kelly K; Christensen S; Daskilewicz K; Doherty K; Bekker LG; Hou T; Wood R; Francke JA; Wools-Kaloustian K; Freedberg KA; Walensky RP
    PLoS One; 2015; 10(3):e0117751. PubMed ID: 25756498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Priorities for antiretroviral therapy research in sub-Saharan Africa: a 2002 consensus conference in Zambia.
    Zulu I; Schuman P; Musonda R; Chomba E; Mwinga K; Sinkala M; Chisembele M; Mwaba P; Kasonde D; Vermund SH
    J Acquir Immune Defic Syndr; 2004 Jul; 36(3):831-4. PubMed ID: 15213567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolving care of HIV-infected pregnant women in Jamaica--from nevirapine to HAART.
    Johnson N; Palmer P; Samuels LA; Morgan O; Onyonyor A; Anderson M; Moore J; Billings C; Harvey KM; Mullings A; McDonald D; Alexander G; Smikle MF; Williams EW; Davis D; Christie CD
    West Indian Med J; 2008 Jun; 57(3):216-22. PubMed ID: 19583119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns of HIV Care Clinic Attendance and Adherence to Antiretroviral Therapy Among Pregnant and Breastfeeding Women Living With HIV in the Context of Option B+ in Zimbabwe.
    Erlwanger AS; Joseph J; Gotora T; Muzunze B; Orne-Gliemann J; Mukungunugwa S; Farley T; Mangwiro AZ
    J Acquir Immune Defic Syndr; 2017 Jun; 75 Suppl 2():S198-S206. PubMed ID: 28498190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial.
    Price JT; Vwalika B; Freeman BL; Cole SR; Mulenga HB; Winston J; Mbewe FM; Chomba E; Mofenson LM; Rouse DJ; Goldenberg RL; Stringer JSA
    BMC Pregnancy Childbirth; 2019 Feb; 19(1):81. PubMed ID: 30813934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Same-day antiretroviral therapy (ART) initiation in pregnancy is not associated with viral suppression or engagement in care: A cohort study.
    Langwenya N; Phillips TK; Brittain K; Zerbe A; Abrams EJ; Myer L
    J Int AIDS Soc; 2018 Jun; 21(6):e25133. PubMed ID: 29939483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal time on HAART for prevention of mother-to-child transmission of HIV.
    Chibwesha CJ; Giganti MJ; Putta N; Chintu N; Mulindwa J; Dorton BJ; Chi BH; Stringer JS; Stringer EM
    J Acquir Immune Defic Syndr; 2011 Oct; 58(2):224-8. PubMed ID: 21709566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ensuring HIV-infected pregnant women start antiretroviral treatment: an operational cohort study from Lilongwe, Malawi.
    Weigel R; Hosseinipour MC; Feldacker C; Gareta D; Tweya H; Chiwoko J; Gumulira J; Kalulu M; Mofolo I; Kamanga E; Mwale G; Kadzakumanja A; Jere E; Phiri S
    Trop Med Int Health; 2012 Jun; 17(6):751-9. PubMed ID: 22487553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD4+ cell count testing more effective than HIV disease clinical staging in identifying pregnant and postpartum women eligible for antiretroviral therapy in resource-limited settings.
    Carter RJ; Dugan K; El-Sadr WM; Myer L; Otieno J; Pungpapong N; Toro PL; Abrams EJ;
    J Acquir Immune Defic Syndr; 2010 Nov; 55(3):404-10. PubMed ID: 20595905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The reliability of point-of-care CD4 testing in identifying HIV-infected pregnant women eligible for antiretroviral therapy.
    Mnyani CN; McIntyre JA; Myer L
    J Acquir Immune Defic Syndr; 2012 Jul; 60(3):260-4. PubMed ID: 22487589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.
    Aaron E; Kempf MC; Criniti S; Tedaldi E; Gracely E; Warriner A; Kumar R; Bachmann LH
    PLoS One; 2010 Sep; 5(9):e12617. PubMed ID: 20838641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of CD4 cell count, viral load, and other markers for the prediction of mortality among HIV-1-infected Kenyan pregnant women.
    Brown ER; Otieno P; Mbori-Ngacha DA; Farquhar C; Obimbo EM; Nduati R; Overbaugh J; John-Stewart GC
    J Infect Dis; 2009 May; 199(9):1292-300. PubMed ID: 19317628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia.
    Kuhn L; Semrau K; Ramachandran S; Sinkala M; Scott N; Kasonde P; Mwiya M; Kankasa C; Decker D; Thea DM; Aldrovandi GM
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):132-6. PubMed ID: 19506483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of antiretroviral therapy treatment failure among HIV-infected pregnant women at first antenatal care: PMTCT Option B+ in Malawi.
    Chagomerana MB; Miller WC; Tang JH; Hoffman IF; Harrington BJ; DiPrete B; Wallie S; Jumbe A; Limarzi L; Hosseinipour MC
    PLoS One; 2018; 13(12):e0209052. PubMed ID: 30543685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD4+ cell count and risk for antiretroviral drug resistance among women using peripartum nevirapine for perinatal HIV prevention.
    Dorton BJ; Mulindwa J; Li MS; Chintu NT; Chibwesha CJ; Mbewe F; Frenkel LM; Stringer JS; Chi BH
    BJOG; 2011 Mar; 118(4):495-9. PubMed ID: 21199294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.